{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:34:18Z","timestamp":1790037258188,"version":"4.0.1"},"reference-count":194,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.jash.2007.12.002","type":"journal-article","created":{"date-parts":[[2008,6,3]],"date-time":"2008-06-03T15:46:25Z","timestamp":1212507985000},"page":"239-266","source":"Crossref","is-referenced-by-count":13,"title":["Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome"],"prefix":"10.1016","volume":"2","author":[{"given":"Melvin R.","family":"Hayden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Sowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jash.2007.12.002_bib1","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2007.12.002_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJM199601043340103","article-title":"Blood pressure and end\u2013stage renal disease in men","volume":"334","author":"Klag","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2007.12.002_bib3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12- year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2007.12.002_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1557-0843(06)80005-9","article-title":"Hypertension in type 2 diabetes mellitus","volume":"1","author":"Hayden","year":"2006","journal-title":"Insulin"},{"key":"10.1016\/j.jash.2007.12.002_bib5","doi-asserted-by":"crossref","first-page":"H1597","DOI":"10.1152\/ajpheart.00026.2004","article-title":"Insulin resistance and hypertension","volume":"286","author":"Sowers","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jash.2007.12.002_bib6","first-page":"86","article-title":"Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus","volume":"3","author":"Hayden","year":"2002","journal-title":"JOP"},{"key":"10.1016\/j.jash.2007.12.002_bib7","doi-asserted-by":"crossref","first-page":"796","DOI":"10.4065\/81.6.796","article-title":"Effect of antihypertensive agents on the development of type 2 diabetes mellitus","volume":"81","author":"Stump","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jash.2007.12.002_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00129784-200606030-00001","article-title":"The effect of antihypertensive agents on new\u2013onset diabetes mellitus: time to amend the guidelines?","volume":"6","author":"Aksnes","year":"2006","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jash.2007.12.002_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.0197-3118.2006.05523.x","article-title":"Nonalcoholic steatohepatitis and the cardiometabolic syndrome","volume":"1","author":"Abdeen","year":"2006","journal-title":"J Cardiometab Syndr"},{"key":"10.1016\/j.jash.2007.12.002_bib10","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2007.12.002_bib11","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1524-6175.2006.05156.x","article-title":"Chronic kidney disease and the cardiometabolic syndrome","volume":"8","author":"Whaley-Connell","year":"2006","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jash.2007.12.002_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM199602083340607","article-title":"Hypertension and associated metabolic abnormalities\u2014the role of insulin resistance and the sympathoadrenal system","volume":"334","author":"Reaven","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2007.12.002_bib13","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1210\/jc.86.2.713","article-title":"Insulin resistance and cardiovascular disease","volume":"86","author":"McFarlane","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jash.2007.12.002_bib14","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1001\/archinte.152.8.1649","article-title":"Fasting serum insulin levels in essential hypertension","volume":"152","author":"Denker","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jash.2007.12.002_bib15","doi-asserted-by":"crossref","first-page":"I12","DOI":"10.1161\/01.HYP.23.1_Suppl.I12","article-title":"Hyperinsulinemia in normotensive offspring of hypertensive parents","volume":"23","author":"Grunfeld","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.HYP.37.2.433","article-title":"Endothelial dysfunction and salt\u2013sensitive hypertension in spontaneously diabetic Goto\u2013Kakizaki rats","volume":"37","author":"Cheng","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0895-7061(94)00160-D","article-title":"Increased basal arterial smooth muscle glucose transport in the Zucker rat","volume":"8","author":"Standley","year":"1995","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1079\/PNS2005445","article-title":"The metabolic syndrome: the crossroads of diet and genetics","volume":"64","author":"Roche","year":"2005","journal-title":"Proc Nutr Soc"},{"issue":"Suppl 1","key":"10.1016\/j.jash.2007.12.002_bib19","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1017\/S0007114500000945","article-title":"Genetics of the metabolic syndrome","volume":"83","author":"Groop","year":"2000","journal-title":"Br J Nutr"},{"issue":"Suppl 4","key":"10.1016\/j.jash.2007.12.002_bib20","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1098-3597(03)90062-7","article-title":"Insulin as an anti\u2013inflammatory and antiatherosclerotic hormone","author":"Dandona","year":"2003","journal-title":"Clin Cornerstone"},{"key":"10.1016\/j.jash.2007.12.002_bib21","doi-asserted-by":"crossref","first-page":"E353","DOI":"10.1152\/ajpendo.00402.2004","article-title":"Abrogation of oxidative stress improves insulin sensitivity in the Ren\u20132 rat model of tissue angiotensin II overexpression","volume":"288","author":"Blendea","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jash.2007.12.002_bib22","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-201X.2004.01332.x","article-title":"Transgenic mice for studies of the renin\u2013angiotensin system in hypertension","volume":"181","author":"Lavoie","year":"2004","journal-title":"Acta Physiol Scand"},{"key":"10.1016\/j.jash.2007.12.002_bib23","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1161\/01.CIR.98.22.2453","article-title":"Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms","volume":"98","author":"Nickenig","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2007.12.002_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2337\/diab.32.1.35","article-title":"Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man","volume":"32","author":"DeFronzo","year":"1983","journal-title":"Diabetes"},{"key":"10.1016\/j.jash.2007.12.002_bib25","doi-asserted-by":"crossref","first-page":"30H","DOI":"10.1016\/S0002-9149(03)00432-6","article-title":"Mechanisms by which angiotensin\u2013converting enzyme inhibitors prevent diabetes and cardiovascular disease","volume":"91","author":"McFarlane","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jash.2007.12.002_bib26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00041552-200405000-00010","article-title":"Impact of the renin\u2013angiotensin system on lipid and carbohydrate metabolism","volume":"13","author":"Strazzullo","year":"2004","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib27","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1097\/00004872-200410000-00021","article-title":"Blockade of the renin\u2013angiotensin system decreases adipocyte size with improvement in insulin sensitivity","volume":"22","author":"Furuhashi","year":"2004","journal-title":"J Hypertens"},{"issue":"Suppl 4","key":"10.1016\/j.jash.2007.12.002_bib28","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1038\/sj.ijo.0801501","article-title":"Angiotensinogen, angiotensin II and adipose tissue development","volume":"24","author":"Ailhaud","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.jash.2007.12.002_bib29","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2337\/diabetes.51.6.1699","article-title":"Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors","volume":"51","author":"Janke","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.jash.2007.12.002_bib30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2337\/diabetes.54.1.8","article-title":"Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes","volume":"54","author":"Ritov","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jash.2007.12.002_bib31","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1172\/JCI118648","article-title":"Quantitative trait locus mapping of human blood pressure to a genetic region at or near the lipoprotein lipase gene locus on chromosome 8p22","volume":"97","author":"Wu","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jash.2007.12.002_bib32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.metabol.2004.07.021","article-title":"High lipoprotein lipase activity increases insulin sensitivity in transgenic rabbits","volume":"54","author":"Liu","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.jash.2007.12.002_bib33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1152\/jappl.2001.91.2.687","article-title":"Reduced lipoprotein lipase activity in postural skeletal muscle during aging","volume":"91","author":"Bey","year":"2001","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.jash.2007.12.002_bib34","doi-asserted-by":"crossref","first-page":"E1016","DOI":"10.1152\/ajpendo.1998.275.6.E1016","article-title":"Role of local contractile activity and muscle fiber type on LPL regulation during exercise","volume":"275","author":"Hamilton","year":"1998","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jash.2007.12.002_bib35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1113\/jphysiol.2003.045591","article-title":"Suppression of skeletal muscle lipoprotein lipase activity during physical inactivity: a molecular reason to maintain daily low\u2013intensity activity","volume":"551","author":"Bey","year":"2003","journal-title":"J Physiol"},{"key":"10.1016\/j.jash.2007.12.002_bib36","doi-asserted-by":"crossref","first-page":"688","DOI":"10.2337\/diacare.26.3.688","article-title":"Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?","volume":"26","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2007.12.002_bib37","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/01.HYP.0000035706.28494.09","article-title":"Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance","volume":"40","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.med.0000216961.44128.9e","article-title":"Role of angiotensin II in diabetic cardiovascular and renal disease","volume":"13","author":"Hayden","year":"2006","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.jash.2007.12.002_bib39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.0197-3118.2006.05454.x","article-title":"Introduction: organ involvement in the cardiometabolic syndrome","volume":"1","author":"Hayden","year":"2006","journal-title":"J Cardiometab Syndr"},{"key":"10.1016\/j.jash.2007.12.002_bib40","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1210\/en.143.2.339","article-title":"Mini-review: secondary \u03b2\u2013cell failure in type 2 diabetes\u2013a convergence of glucotoxicity and lipotoxicity","volume":"143","author":"Poitout","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.jash.2007.12.002_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1677\/jme.0.0260155","article-title":"Tissue renin\u2013angiotensin system: its expression, localization, regulation and potential role in the pancreas","volume":"26","author":"Leung","year":"2001","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.jash.2007.12.002_bib42","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S1357-2725(02)00179-6","article-title":"A local pancreatic renin\u2013angiotensin system: endocrine and exocrine roles","volume":"35","author":"Leung","year":"2003","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.jash.2007.12.002_bib43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00125-003-1295-1","article-title":"Evidence for a local angiotensin\u2013generating system and dose\u2013dependent inhibition of glucose\u2013stimulated insulin release by angiotensin II in isolated pancreatic islets","volume":"47","author":"Lau","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.jash.2007.12.002_bib44","first-page":"26","article-title":"The renin\u2013angiotensin system in the endocrine pancreas","volume":"2","author":"Carlsson","year":"2001","journal-title":"JOP"},{"key":"10.1016\/j.jash.2007.12.002_bib45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s001250050880","article-title":"Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats","volume":"41","author":"Carlsson","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.jash.2007.12.002_bib46","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1161\/01.HYP.30.5.1156","article-title":"Angiotensin II affects basal, pulsatile, and glucose\u2013stimulated insulin secretion in humans","volume":"30","author":"Fliser","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib47","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.2337\/diabetes.52.11.2759","article-title":"Prevalence and clinicopathological characteristics of islet amyloid in Chinese patients with type 2 diabetes","volume":"52","author":"Zhao","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.jash.2007.12.002_bib48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1559-4564.2007.06159.x","article-title":"Islet amyloid and fibrosis in the cardiometabolic syndrome and type 2 diabetes mellitus","volume":"2","author":"Hayden","year":"2007","journal-title":"J Cardiometab Syndr"},{"key":"10.1016\/j.jash.2007.12.002_bib49","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2337\/diabetes.53.4.989","article-title":"Improved islet morphology after blockade of the renin\u2013angiotensin system in the ZDF rat","volume":"53","author":"Tikellis","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.jash.2007.12.002_bib50","first-page":"725","article-title":"Ultra-structural islet study of early fibrosis in the Ren2 rat model of hypertension","volume":"8","author":"Hayden","year":"2007","journal-title":"JOP"},{"key":"10.1016\/j.jash.2007.12.002_bib51","first-page":"772","article-title":"Longitudinal ultrastructure study of islet amyloid in the HIP rat model of type 2 diabetes mellitus","volume":"232","author":"Hayden","year":"2007","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.jash.2007.12.002_bib52","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1089\/ars.2007.1640","article-title":"Redox imbalance in diabetes","volume":"9","author":"Hayden","year":"2007","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.jash.2007.12.002_bib53","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/ars.2007.1610","article-title":"Isletopathy in type 2 diabetes mellitus: implications of islet RAS, islet fibrosis, islet amyloid, remodeling, and oxidative stress","volume":"9","author":"Hayden","year":"2007","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.jash.2007.12.002_bib54","first-page":"124","article-title":"\u201cA\u201d is for amylin and amyloid in type 2 diabetes mellitus","volume":"2","author":"Hayden","year":"2001","journal-title":"JOP"},{"key":"10.1016\/j.jash.2007.12.002_bib55","first-page":"287","article-title":"Type 2 diabetes mellitus as a conformational disease","volume":"6","author":"Hayden","year":"2005","journal-title":"JOP"},{"key":"10.1016\/j.jash.2007.12.002_bib56","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","article-title":"Purification and characterization of a peptide from amyloid\u2013rich pancreases of type 2 diabetic patients","volume":"84","author":"Cooper","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jash.2007.12.002_bib57","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/oby.2002.147","article-title":"Amylin, food intake, and obesity","volume":"10","author":"Reda","year":"2002","journal-title":"Obes Res"},{"key":"10.1016\/j.jash.2007.12.002_bib58","doi-asserted-by":"crossref","first-page":"R1777","DOI":"10.1152\/ajpregu.1998.274.6.R1777","article-title":"Anorectic effect of amylin is not transmitted by capsaicin\u2013sensitive nerve fibers","volume":"274","author":"Lutz","year":"1998","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jash.2007.12.002_bib59","doi-asserted-by":"crossref","first-page":"F289","DOI":"10.1152\/ajprenal.1996.270.2.F289","article-title":"Amylin binding in rat renal cortex, stimulation of adenylyl cyclase, and activation of plasma renin","volume":"270","author":"Wookey","year":"1996","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jash.2007.12.002_bib60","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/01.HYP.26.3.460","article-title":"Amylin stimulates plasma renin concentration in humans","volume":"26","author":"Cooper","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib61","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.2337\/diabetes.52.9.2304","article-title":"Increased \u03b2-cell apoptosis prevents adaptive increase in \u03b2-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.jash.2007.12.002_bib62","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1097\/00004872-200018110-00012","article-title":"Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk","volume":"18","author":"Kailasam","year":"2000","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib63","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.12.002_bib64","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2007.12.002_bib65","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.12.002_bib66","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2007.12.002_bib67","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2007.12.002_bib68","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/01.CIR.0000054611.89228.92","article-title":"Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD)","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2007.12.002_bib69","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2007.12.002_bib70","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/archinte.166.7.797","article-title":"Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease","volume":"166","author":"Thornley-Brown","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jash.2007.12.002_bib71","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1097\/00004872-200209000-00035","article-title":"Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study","volume":"20","author":"Lindholm","year":"2002","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib72","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.12.002_bib73","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.104.528166","article-title":"Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure","volume":"112","author":"Yusuf","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2007.12.002_bib74","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/00004872-200308000-00022","article-title":"Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE Study)","volume":"21","author":"Lindholm","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib75","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.12.002_bib76","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.HYP.0000236119.96301.f2","article-title":"The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy","volume":"48","author":"Julius","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib77","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/bmj.309.6949.226","article-title":"Effects of low-dose versus conventional dose thiazide diuretic on insulin action in essential hypertension","volume":"309","author":"Harper","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.jash.2007.12.002_bib78","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2337\/dc05-2366","article-title":"Antihypertensive medications and the risk of incident type 2 diabetes","volume":"29","author":"Taylor","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2007.12.002_bib79","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1038\/sj.jhh.1001888","article-title":"New concepts in blood pressure-lowering management in diabetic patients: the case for early ACE inhibitor combination therapy with diuretics","volume":"19","author":"Mogensen","year":"2005","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib80","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00129784-200505010-00003","article-title":"Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide","volume":"5","author":"Kjeldsen","year":"2005","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jash.2007.12.002_bib81","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/08037050510008832","article-title":"Angiotensin-receptor blockers and diuretics-advantages of combination","volume":"14","author":"Mimran","year":"2005","journal-title":"Blood Press"},{"key":"10.1016\/j.jash.2007.12.002_bib82","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/qjmed\/hcl059","article-title":"Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control","volume":"99","author":"Sarafidis","year":"2006","journal-title":"QJM"},{"key":"10.1016\/j.jash.2007.12.002_bib83","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.numecd.2005.04.005","article-title":"Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism","volume":"16","author":"Pessina","year":"2006","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jash.2007.12.002_bib84","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1524-6175.2004.03751.x","article-title":"Hypertension, the metabolic syndrome, and the risk of developing diabetes: is it time to change the guidelines?","volume":"6","author":"Weber","year":"2004","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jash.2007.12.002_bib85","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/hy0102.102293","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril","volume":"39","author":"Nussberger","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib86","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis","volume":"369","author":"Elliott","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.12.002_bib87","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0002-8703(83)90124-2","article-title":"Thiazide-induced disturbances in carbohydrate, lipid, and potassium metabolism","volume":"106","author":"Perez-Stable","year":"1983","journal-title":"Am Heart J"},{"key":"10.1016\/j.jash.2007.12.002_bib88","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2337\/diacare.14.3.203","article-title":"Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism","volume":"14","author":"Lithell","year":"1991","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2007.12.002_bib89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00004872-199103000-00005","article-title":"Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly","volume":"9","author":"Fletcher","year":"1991","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib90","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/archinte.158.7.741","article-title":"Influence of long\u2013term, low\u2013dose, diuretic\u2013based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program","volume":"158","author":"Savage","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jash.2007.12.002_bib91","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.HYP.0000125726.92964.ab","article-title":"Adverse prognostic significance of new diabetes in treated hypertensive subjects","volume":"43","author":"Verdecchia","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib92","first-page":"257","article-title":"Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non\u2013selective beta\u2013blockers and thiazide diuretics during 15 years treatment of middle\u2013aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden","volume":"8","author":"Samuelsson","year":"1994","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib93","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJM200003303421310","article-title":"Antihypertensive therapy and the risk of type 2 diabetes mellitus","volume":"342","author":"Sowers","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2007.12.002_bib94","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/archinte.166.20.2191","volume":"166","author":"Barzilay","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jash.2007.12.002_bib95","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1097\/01.hjh.0000177537.91527.09","article-title":"The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension","volume":"23","author":"Mason","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib96","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.2337\/dc06-1373","article-title":"Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome","volume":"29","author":"Bakris","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2007.12.002_bib97","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2337\/diacare.27.1.247","article-title":"Antihypertensive therapy and incidence of type 2 diabetes: a systematic review","volume":"27","author":"Padwal","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2007.12.002_bib98","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1210\/jcem-34-1-235","article-title":"Glucose intolerance with hypokalemia: an increased proportion of circulating proinsulin-like component","volume":"34","author":"Gorden","year":"1972","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jash.2007.12.002_bib99","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2337\/diabetes.32.2.106","article-title":"Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium","volume":"32","author":"Helderman","year":"1983","journal-title":"Diabetes"},{"key":"10.1016\/j.jash.2007.12.002_bib100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/107602960501100203","article-title":"Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension","volume":"11","author":"Papadakis","year":"2005","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jash.2007.12.002_bib101","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.amjhyper.2005.03.731","article-title":"Antioxidative protection in hypertensive patients treated with diuretics","volume":"18","author":"Skalska","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib102","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jash.2007.12.002_bib103","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/bmj.298.6681.1152","article-title":"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double-blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients","volume":"298","author":"Pollare","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.jash.2007.12.002_bib104","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/08037059209077499","article-title":"Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients","volume":"1","author":"Lithell","year":"1992","journal-title":"Blood Press"},{"key":"10.1016\/j.jash.2007.12.002_bib105","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus","volume":"342","author":"Gress","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2007.12.002_bib106","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-7061(98)00141-1","article-title":"Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of \u03b2-blocking agents?","volume":"11","author":"Jacob","year":"1998","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib107","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/bmj.1.6157.159","article-title":"Beta-adrenoceptor-blocking drugs and blood sugar control in diabetes mellitus","volume":"1","author":"Wright","year":"1979","journal-title":"BMJ"},{"key":"10.1016\/j.jash.2007.12.002_bib108","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.pharmthera.2003.09.001","article-title":"Vasodilating \u03b2-adrenoceptor blockers as cardiovascular therapeutics","volume":"100","author":"Toda","year":"2003","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jash.2007.12.002_bib109","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1527-3466.2004.tb00138.x","article-title":"Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol","volume":"22","author":"Kuroedov","year":"2004","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.jash.2007.12.002_bib110","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/00004872-200108000-00011","article-title":"Effects of nebivolol and atenolol on insulin sensitivity and hemodynamics in hypertensive patients","volume":"19","author":"Poirier","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib111","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01.hjh.0000209993.26057.de","article-title":"Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients","volume":"24","author":"Celik","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib112","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/01.HYP.0000239207.82326.29","article-title":"Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats","volume":"48","author":"Oelze","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib113","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1161\/CIRCULATIONAHA.105.556233","article-title":"Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans","volume":"112","author":"Mason","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2007.12.002_bib114","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1016\/j.bmc.2006.02.023","article-title":"Antioxidant activity of \u03b2-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species?","volume":"14","author":"Gomes","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jash.2007.12.002_bib115","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/01.mjt.0000155111.46961.03","article-title":"Suppression of hyperglycemia-induced superoxide formation and endothelin-1 gene expression by carvedilol","volume":"13","author":"Horani","year":"2006","journal-title":"Am J Ther"},{"key":"10.1016\/j.jash.2007.12.002_bib116","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/01.hjh.0000160216.86597.ff","article-title":"Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation","volume":"23","author":"Fratta Pasini","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib117","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0895-7061(02)03019-4","article-title":"Improvement of insulin sensitivity by a long-acting nifedipine preparation (nifedipine-CR) in patients with essential hypertension","volume":"15","author":"Koyama","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib118","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1291\/hypres.26.383","article-title":"Effect of cilnidipine on insulin sensitivity in patients with essential hypertension","volume":"26","author":"Yagi","year":"2003","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2007.12.002_bib119","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.2165\/00003495-200464170-00011","article-title":"Manidipine: a review of its use in the management of hypertension","volume":"64","author":"McKeage","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.jash.2007.12.002_bib120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000088854","article-title":"Antioxidant and nitric oxide-sparing actions of dihydropyridines and ACE inhibitors differ in human endothelial cells","volume":"76","author":"Lob","year":"2006","journal-title":"Pharmacology"},{"key":"10.1016\/j.jash.2007.12.002_bib121","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejphar.2005.10.046","article-title":"Endothelial antioxidant actions of dihydropyridines and angiotensin converting enzyme inhibitors","volume":"529","author":"Rosenkranz","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jash.2007.12.002_bib122","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/01.fjc.0000196241.96759.71","article-title":"Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension","volume":"47","author":"Martinez","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jash.2007.12.002_bib123","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1291\/hypres.28.107","article-title":"Benidipine, a long-acting calcium channel blocker, inhibits oxidative stress in polymorphonuclear cells in patients with essential hypertension","volume":"28","author":"Yasunari","year":"2005","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2007.12.002_bib124","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(05)67186-3","article-title":"Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)","volume":"366","author":"Poulter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.12.002_bib125","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1161\/01.HYP.38.3.705","article-title":"Treatment of obesity hypertension and diabetes syndrome","volume":"38","author":"Zanella","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib126","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJM199304013281303","article-title":"Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo","volume":"328","author":"Materson","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2007.12.002_bib127","first-page":"437","article-title":"Doxazosin versus bendrofluazide: a comparison of the metabolic effects in British South Asians with hypertension","volume":"55","author":"Hobbs","year":"2005","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.jash.2007.12.002_bib128","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0895-7061(95)00396-7","article-title":"Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men: relationship to changes in skeletal muscle blood flow","volume":"9","author":"Andersson","year":"1996","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib129","doi-asserted-by":"crossref","first-page":"33S","DOI":"10.1016\/S0002-9343(96)00266-5","article-title":"Therapeutic challenges in the obese diabetic patient with hypertension","volume":"101","author":"Bakris","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.jash.2007.12.002_bib130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00019501-200502000-00012","article-title":"The vascular effects of doxazosin in hypertension complicated by metabolic syndrome","volume":"16","author":"Dell'Omo","year":"2005","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.jash.2007.12.002_bib131","doi-asserted-by":"crossref","first-page":"150S","DOI":"10.1016\/0895-7061(96)00290-7","article-title":"Hyperinsulinemia, insulin resistance, and the treatment of hypertension","volume":"9","author":"Lithell","year":"1996","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib132","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/10641960500511570","article-title":"Effect of doxazosin on oxidative stress related proteins in essential hypertensive patients","volume":"28","author":"Calo","year":"2006","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib133","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jcp.10294","article-title":"Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition","volume":"196","author":"Henriksen","year":"2003","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jash.2007.12.002_bib134","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrd873","article-title":"Drugs targeting the renin-angiotensin-aldosterone system","volume":"1","author":"Zaman","year":"2002","journal-title":"Nature Rev Drug Disc"},{"key":"10.1016\/j.jash.2007.12.002_bib135","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1681\/ASN.2004100874","article-title":"Renin inhibition: what are the therapeutic opportunities?","volume":"16","author":"Fisher","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jash.2007.12.002_bib136","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1074-5521(00)00134-4","article-title":"Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin","volume":"7","author":"Rahuel","year":"2000","journal-title":"Chem Biol"},{"key":"10.1016\/j.jash.2007.12.002_bib137","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"46","author":"Abuissa","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jash.2007.12.002_bib138","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2337\/diacare.28.9.2261","article-title":"The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes","volume":"28","author":"Gillespie","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jash.2007.12.002_bib139","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00125-004-1485-5","article-title":"Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial","volume":"47","author":"Gerstein","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.jash.2007.12.002_bib140","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","article-title":"Effect of ramipril on the incidence of diabetes","volume":"355","author":"Bosch","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2007.12.002_bib141","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0895-7061(99)00174-0","article-title":"The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats","volume":"13","author":"Higashiura","year":"2000","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib142","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0026-0495(99)90263-9","article-title":"Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat","volume":"48","author":"Nawano","year":"1999","journal-title":"Metabolism"},{"key":"10.1016\/j.jash.2007.12.002_bib143","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-201X.1996.517281000.x","article-title":"Effects of angiotensin-converting enzyme inhibition on arterial, venous and capillary functions in cat skeletal muscle in vivo","volume":"158","author":"Ekelund","year":"1996","journal-title":"Acta Physiol Scand"},{"key":"10.1016\/j.jash.2007.12.002_bib144","doi-asserted-by":"crossref","first-page":"R332","DOI":"10.1152\/ajpregu.1999.277.1.R332","article-title":"ACE inhibition and glucose transport in insulin-resistant muscle: roles of bradykinin and nitric oxide","volume":"277","author":"Henriksen","year":"1999","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jash.2007.12.002_bib145","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00004872-200101000-00015","article-title":"Quinapril treatment enhances vascular sensitivity to insulin","volume":"19","author":"Feldman","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib146","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1161\/01.ATV.0000187465.55507.85","article-title":"Inhibition of the renin\u2013angiotensin system prevents free fatty acid\u2013induced acute endothelial dysfunction in humans","volume":"25","author":"Watanabe","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jash.2007.12.002_bib147","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1152\/jappl.1999.86.6.2044","article-title":"Interactions of exercise training and ACE inhibition on insulin action in obese Zucker rats","volume":"86","author":"Steen","year":"1999","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.jash.2007.12.002_bib148","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1161\/01.HYP.0000174602.59935.d5","article-title":"Effects of captopril on the renin-angiotensin system, oxidative stress, and endothelin in normal and hypertensive rats","volume":"46","author":"Bolterman","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib149","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.cca.2005.07.021","article-title":"Angiotensin-converting enzyme inhibitor attenuates oxidative stress-induced endothelial cell apoptosis via p38 MAP kinase inhibition","volume":"364","author":"Yu","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jash.2007.12.002_bib150","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbrc.2006.05.144","article-title":"Pancreatic islet blood flow is selectively enhanced by captopril, irbesartan and pravastatin, and suppressed by palmitate","volume":"346","author":"Huang","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jash.2007.12.002_bib151","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/eje.1.02086","article-title":"The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets","volume":"154","author":"Lupi","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jash.2007.12.002_bib152","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.jhh.1001931","article-title":"Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension","volume":"20","author":"Cheung","year":"2006","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib153","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1097\/00004872-200207000-00029","article-title":"Brief losartan treatment in young spontaneously hypertensive rats abates long-term blood pressure elevation by effects on renal vascular structure","volume":"20","author":"Bergstrom","year":"2002","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib154","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/01.hjh.0000163160.60234.15","article-title":"Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE Substudy","volume":"23","author":"Olsen","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib155","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/eje.1.02219","article-title":"Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I","volume":"155","author":"Zandbergen","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jash.2007.12.002_bib156","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.metabol.2006.04.013","article-title":"Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension","volume":"55","author":"Benndorf","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.jash.2007.12.002_bib157","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","article-title":"Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-g activity","volume":"109","author":"Schupp","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2007.12.002_bib158","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.2337\/diabetes.54.12.3442","article-title":"Molecular characterization of new selective peroxisome proliferators-activated receptor-g modulators with angiotensin receptor blocking activity","volume":"54","author":"Schupp","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jash.2007.12.002_bib159","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR\u03b3-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib160","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.metabol.2006.04.011","article-title":"The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin\u2013resistant subjects","volume":"55","author":"Nagel","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.jash.2007.12.002_bib161","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/01.HYP.0000168046.19884.6a","article-title":"PPAR\u03b3-activating angiotensin type-1 receptor blockers induce adiponectin","volume":"46","author":"Clasen","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib162","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1291\/hypres.27.293","article-title":"Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats","volume":"27","author":"Okada","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2007.12.002_bib163","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/01.HYP.0000125142.41703.64","article-title":"Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice","volume":"43","author":"Shiuchi","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib164","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.amjhyper.2005.05.022","article-title":"Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt\u2013induced hypertension","volume":"18","author":"Bayorh","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0002-9149(01)02323-2","article-title":"From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis","volume":"89","author":"Yusuf","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jash.2007.12.002_bib166","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2004.03.020","volume":"148","author":"Teo","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.jash.2007.12.002_bib167","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.12.002_bib168","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2007.12.002_bib169","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2007.12.002_bib170","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11906-000-0027-x","article-title":"Spironolactone in congestive heart failure","volume":"2","author":"Soberman","year":"2000","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.jash.2007.12.002_bib171","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mce.2003.10.009","article-title":"Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies","volume":"217","author":"Pitt","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jash.2007.12.002_bib172","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11906-007-0018-2","article-title":"The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy","volume":"9","author":"Epstein","year":"2007","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.jash.2007.12.002_bib173","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","article-title":"Effects of eplerenone versus losartan in patients with low-renin hypertension","volume":"150","author":"Weinberger","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.jash.2007.12.002_bib174","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11906-007-0019-1","article-title":"The metabolic syndrome in primary aldosteronism","volume":"9","author":"Fallo","year":"2007","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.jash.2007.12.002_bib175","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1210\/jc.2005-1733","article-title":"Prevalence and characteristics of the metabolic syndrome in primary aldosteronism","volume":"91","author":"Fallo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jash.2007.12.002_bib176","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1210\/en.2006-1691","article-title":"Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling","volume":"148","author":"Stas","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.jash.2007.12.002_bib177","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3317\/jraas.2003.008","article-title":"Potential of renin inhibition in cardiovascular disease","volume":"4","author":"Stanton","year":"2003","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.jash.2007.12.002_bib178","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/HJH.0b013e3280103a6b","article-title":"Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide","volume":"25","author":"Villamil","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib179","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","article-title":"Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension","volume":"49","author":"Oh","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jash.2007.12.002_bib180","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/sj.jhh.1002220","article-title":"A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension","volume":"21","author":"Strasser","year":"2007","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib181","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.HYP.0000101688.17370.87","article-title":"Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren","volume":"42","author":"Stanton","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib182","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients","volume":"111","author":"Gradman","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2007.12.002_bib183","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1524-6175.2007.06614.x","article-title":"Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy","volume":"9","author":"Drummond","year":"2007","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib184","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/HYPERTENSIONAHA.106.084301","article-title":"Direct renin inhibition with aliskiren in obese patients with arterial hypertension","volume":"49","author":"Jordan","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib185","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.12.002_bib186","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3317\/jraas.2007.028","article-title":"Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension","volume":"8","author":"Uresin","year":"2007","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.jash.2007.12.002_bib187","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0006-291X(03)01451-7","article-title":"Structure-based design of aliskiren, a novel orally effective renin inhibitor","volume":"308","author":"Wood","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jash.2007.12.002_bib188","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00004872-200502000-00025","article-title":"Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats","volume":"23","author":"Wood","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib189","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0895-7061(01)02140-9","article-title":"Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women","volume":"14","author":"Fogari","year":"2001","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jash.2007.12.002_bib190","first-page":"S49","article-title":"Cough and inhibition of the renin-angiotensin system","volume":"11","author":"Karlberg","year":"1993","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.jash.2007.12.002_bib191","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.HYP.23.1.44","article-title":"Responses to converting enzyme and renin inhibition: role of angiotensin II in humans","volume":"23","author":"Fisher","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2007.12.002_bib192","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(06)69701-8","article-title":"Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study","volume":"368","author":"Lindstrom","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jash.2007.12.002_bib193","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2840-4-1","article-title":"Isolated low high density lipoprotein-cholesterol (HDL-C): implications of global risk reduction","volume":"4","author":"Hayden","year":"2005","journal-title":"Cardiovasc Diabet"},{"key":"10.1016\/j.jash.2007.12.002_bib194","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF02892289","article-title":"Compliance with cardiovascular disease prevention strategies: a review of the research","volume":"19","author":"Burke","year":"1997","journal-title":"Ann Behav Med"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171107002525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171107002525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T21:32:40Z","timestamp":1557610360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171107002525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":194,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S1933171107002525"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2007.12.002","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}